RxDoctor Payments Data

Nishant Shroff, MD

Internal Medicine · Douglasville, GANPI 1386808947

Payments from drug & device makers

$7,866in general payments, 2019–2025

Across 458 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$985
  • AstraZeneca$712
  • Amgen$652
  • Lilly USA, LLC$486
  • Abbott$415
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,834100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,866 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$150,213
Medicare patients
311
Services billed
1,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide221$246,744
MounjaroTirzepatide103$112,897
TrulicityDulaglutide84$95,676
JardianceEmpagliflozin85$83,085
JanuviaSitagliptin Phosphate72$81,952
FarxigaDapagliflozin Propanediol56$63,107
MyrbetriqMirabegron82$59,408
EliquisApixaban54$49,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$35,576
Repatha SureclickEvolocumab38$31,091
ProliaDenosumab18$31,069
XareltoRivaroxaban41$29,303
EntrestoSacubitril/Valsartan19$20,891
TradjentaLinagliptin19$19,146
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$19,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$985$261,097232 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25$486$213,127198 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$225$109,788120 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$712$82,62292 claims
MerckJanuvia$207$81,95272 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$283$63,72779 claims
Astellas Pharma US IncMyrbetriq$199$59,40882 claims
PfizerEliquis$1,009$49,20054 claims
AmgenProlia$652$31,06918 claims
Johnson & JohnsonXarelto$209$29,30341 claims
NovartisEntresto$396$20,89119 claims
AbbVieSynthroid$194$3,69042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →